MYC on the Path to Cancer | Zendy

Chi V. Dang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

MYC on the Path to Cancer

Author(s) -

Chi V. Dang

Publication year - 2012

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2012.03.003

Subject(s) - biology , oncogene , microrna , cancer , bromodomain , proto oncogene proteins c myc , cancer research , cancer cell , function (biology) , glutamine , in vivo , gene expression , microbiology and biotechnology , gene , epigenetics , biochemistry , genetics , cell cycle , amino acid

The MYC oncogene contributes to the genesis of many human cancers. Recent insights into its expression and function have led to therapeutic opportunities. MYC's activation by bromodomain proteins could be inhibited by drug-like molecules, resulting in tumor inhibition in vivo. Tumor growth can also be curbed by pharmacologically uncoupling bioenergetic pathways involving glucose or glutamine metabolism from Myc-induced cellular biomass accumulation. Other approaches to halt Myc on the path to cancer involve targeting Myc-Max dimerization or Myc-induced microRNA expression. Here the richness of our understanding of MYC is reviewed, highlighting new biological insights and opportunities for cancer therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research